Author

S. C. Kales

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 4 Approach:experimental assay· 3 Research Focus:benchmarking· 1 Approach:comparative / phylogenetic analysis· 1 Research Focus:database / resource· 1 Organism:human· 1 Assay:proteomics· 1 Research Focus:variant effect prediction· 1

Frequent Co-Authors

A. Simeonov· 4 shared J. H. Shrimp· 3 shared M. D. Hall· 3 shared M. Shen· 3 shared C. Klumpp-Thomas· 2 shared C. Z. Chen· 2 shared H. Guo· 2 shared K. M. Wilson· 2 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersBiochemistry

A. Simeonov

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Comparative analysis of drug-like EP300/CREBBP acetyltransferase inhibitors

M. C. Crawford, D. R. Tripu, S. A. Barritt, Y. Jing, D. Gallimore, S. C. Kales, N. V. Bhanu, Y. Xiong, Y. Fang, K. A. T. Butler, C. A. LeClair, N. P. Coussens, A. Simeonov, B. A. Garcia, C. C. Dibble, J. L. Meier

This study compares the biochemical and biological potencies of three EP300/CREBBP acetyltransferase inhibitors and demonstrates their utility in investigating epigenetic mechanisms.

bioRxiv · May 15, 2023Biochemistry

A Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19

J. H. Shrimp, J. Janiszewski, C. Z. Chen, M. Xu, K. M. Wilson, S. C. Kales, P. E. Sanderson, P. Shinn, Z. Itkin, H. Guo, M. Shen, C. Klumpp-Thomas, S. G. Michael, W. Zheng, A. Simeonov, M. D. Hall

The paper develops and validates a series of assays to identify TMPRSS2 inhibitors as potential COVID-19 treatments, identifying six compounds with varying clinical statuses.

bioRxiv · Feb 4, 2022Biochemistry

An Enzymatic TMPRSS2 Assay for Assessment of Clinical Candidates and Discovery of Inhibitors as Potential Treatment of COVID-19

J. H. Shrimp, S. C. Kales, P. E. Sanderson, A. Simeonov, M. Shen, M. D. Hall

The paper describes an enzymatic TMPRSS2 assay for inhibitor discovery and profiling of FDA-approved therapeutics, showing varying potencies of tested compounds.

bioRxiv · Jun 23, 2020Biochemistry

Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research

K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, , M. D. Hall

This paper describes the NCATS OpenData Portal, a platform for real-time sharing of drug screening data that accelerates translational research by enabling immediate access to large-scale datasets.

bioRxiv · Jun 4, 2020 · PreprintBiochemistry